California Supreme Court Weighs 'Duty to Innovate' in Gilead Case
The California Supreme Court heard arguments over a 'duty to innovate' in product liability law last week.
Why it matters: The Court's decision could redefine product liability, affecting how manufacturers approach drug safety and innovation. Legal teams advising pharma and tech companies face potential shifts in risk and compliance strategy.
- Oral arguments in Gilead Tenofovir Cases (S283862) took place May 6, 2026.
- About 24,000 HIV patients sued Gilead for allegedly delaying a safer drug, TAF, to protect TDF profits.
- The California Court of Appeal allowed negligence claims to proceed, expanding duty beyond defective products.
- Industry voices warn imposing this duty could have major consequences for manufacturers and consumers.
The California Supreme Court heard oral arguments on May 6, 2026, in the high-profile Gilead Tenofovir Cases (S283862) to decide whether pharmaceutical makers owe a legal duty to innovate by developing and making available safer alternatives.
- Roughly 24,000 HIV patients allege Gilead Sciences intentionally delayed advancement of tenofovir alafenamide (TAF)—viewed as safer than its existing HIV medication tenofovir disoproxil fumarate (TDF)—to maximize TDF's patent window.
- The plaintiffs do not claim TDF itself is defective. Instead, they argue Gilead breached its "duty of reasonable care" to TDF users by not timely developing TAF.
- The 2024 Court of Appeal ruling allowed the negligence claims, holding that manufacturers' duties may require more than simply avoiding defective products.
- General counsel Cory Andrews of the Washington Legal Foundation warned, “Imposing tort liability for non-defective products would be devastating to manufacturers and consumers alike.”
- King & Spalding noted the justices seemed "uncertain about the practical limits and broader implications of using tort law to impose a duty to innovate."
The Supreme Court’s forthcoming decision is expected to set a critical precedent for product liability and innovation standards in California, with ripple effects nationwide, especially for pharmaceutical and technology companies.
By the numbers:
- 24,000 — Number of HIV patients involved in lawsuits against Gilead Sciences
- 2024 — Year Court of Appeal allowed the negligence claim to proceed
- May 6, 2026 — Date California Supreme Court heard oral arguments
Yes, but: There are concerns about unclear boundaries and the potential impact on product pricing and availability if manufacturers face expanded liability for non-defective products.
What's next: A decision from the California Supreme Court is anticipated later this year, which could reshape industry standards.